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Numerous epidemiological studies have demonstrated that diets
rich in fruits and vegetables are protective against several forms of
cancer (Steinmetz and Potter, 1996), and much attention has been
focused on whether naturally occurring dietary components can
modify the mutagenic and carcinogenic effects of environmental
carcinogens. 7,12-dimethylbenz[a]anthracene (DMBA), a model
compound which induces mammary tumorigenesis in rodents
(Huggins et al, 1961), is a member of one such class of carcinogen,
the aryl hydrocarbons. Aryl hydrocarbons bind and activate the
aryl hydrocarbon receptor (AhR), which induces the transcription
of a number of genes (Rowlands and Gustafsson, 1997), includ-
ing the cytochrome P450 1A (CYP1A) enzyme family. CYP1As
mediate the oxidative catabolism of aryl hydrocarbons, generating
genotoxic metabolites which can bind specific residues of DNA,
introducing mutations in key genes and resulting in cellular trans-
formation (Dipple, 1995). Inhibition of the metabolic activation of
carcinogens, either through inhibition of the AhR-mediated signal
transduction pathway or direct enzyme inhibition, is believed to be
an important mechanism in chemoprevention.
Flavonoids are among the most abundant of phytochemicals and
much attention has been focused recently on the effect of
flavonoids on chemically induced in vivo models of carcinogen-
esis. Flavonoids consist of a diverse group of polyphenolic deriva-
tives of benzo-g-pyrone that are ubiquitous in foods of plant origin
such as vegetables, fruit, tea and wine (Formica and Regelson,
1995). Dietary intake of flavonoids has been estimated at 1 g per
day (Kuhnau, 1976), but recent studies have indicated that
consumption varies widely (Hollman and Katan, 1997; Hollman
et al, 1997). In vivo studies have shown that some flavonoids are
effective in preventing chemically induced cancer in rodents,
including DMBA-induced mammary cancer (Verma et al, 1988;
Lamartiniere et al, 1995). Flavonoids exert a multiplicity of
biochemical actions that are believed to be an important part of the
chemopreventive effect of plant-based diets. Various flavonoids
are potent antioxidants (Kono et al, 1997; Noda et al, 1997),
inhibit lipoxygenase and cyclooxygenase (Mirzoeva and Calder,
1996), affect the activity of several hepatic enzymes involved in
activation and detoxification of carcinogens (Canivenc-Lavier et
al, 1996), inhibit cellular proliferation (Tsyrlov et al, 1994; Siess et
al, 1995; Moon et al, 1998), and induce apoptosis of tumour cells
(Csokay et al, 1997). Galangin, a member of the flavonol class of
flavonoids, is present in high concentrations in Alpina officinarum
(common name: China or India root), which has been used as a
spice and as a herbal medicine for a variety of ailments in Asia for
centuries. Galangin has been shown to inhibit the proliferation of
breast tumour cells (So et al, 1996, 1997), and to inhibit the
cytochrome P450-dependent hydroxylation of the aryl hydrocarbon
benzo[a]pyrene in human liver microsomes (Buening et al, 1981).
For this report we have examined the effects of galangin on the
carcinogen activation pathway mediated by the AhR. We have
used the MCF-7 human breast carcinoma cell line because it is
derived from the target tissue of DMBA, the mammary epithe-
lium, and because AhR function and carcinogen activation has
been well characterized in these cells (Christou et al, 1994; Moore
et al, 1994; Dohr et al, 1995; Wang et al, 1995). Furthermore, a
recent study has demonstrated that MCF-7 cells are similar to
normal human mammary epithelial cells with regard to AhR
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strate that galangin inhibits the activation of DMBA by inhibiting
AhR function and CYP1A1 enzyme activity, and thus may be a
promising candidate for in vivo chemoprevention study.
MATERIALS AND METHODS
Materials
Except as noted, all chemicals were from Sigma (St Louis, MO,
USA). All culture vessels were from CoStar (Cambridge, MA,
USA). Galangin (Aldrich, Milwaukee, WI, USA) was dissolved in
dimethylsulphoxide (DMSO) and stored at – 20°C.
Cell culture
MCF-7 cells (American Type Culture Collection, Rockville, MD,
USA) were grown in RPMI-1640 supplemented with 2 mM gluta-
mine and 10% fetal bovine serum (all from BioFluids, Rockville,
MD, USA). Cells were sub-cultured weekly using 0.25%
trypsin/0.05% EDTA (BioFluids). All experiments were carried
out at 37°C and 5% carbon dioxide on confluent cells in growth
medium, except where indicated.
Measurement of DMBA metabolism
All steps were carried out in the dark or under yellow light.
MCF-7 cells in 175 cm2 flasks were incubated in 12 ml of growth
medium containing 0.1 mg ml–1 [3H]DMBA (Amersham,
Arlington Heights, IL, USA) in the presence of DMSO (control),
1 mM, or 10 mM galangin. After 24 h, 1 ml of the medium was
removed and extracted with 1 ml ethyl acetate. [3H]DMBA was
separated from metabolites by thin-layer chromatography. A total
of 5 ml of the organic phase was applied to a 20 ´ 20 cm2 silica
thin-layer chromatography sheet with fluorescent indicator
(Kodak, Rochester, NY, USA). Chromatography was performed in
n-hexane for 80 min. The sheet was dried and 12 1.7-cm strips
were cut, placed in 20 ml BSC-NA organic scintillation fluid
(Amersham) and counted. The parent compound migrated to the
seventh and eighth strips while the metabolites migrated to the first
two strips (counted from the point of application). Spontaneous
decomposition of [3H]DMBA was determined by incubating flasks
without cells under the same conditions. The amount of metabo-
lites formed in blank flasks (20 ± 0.58%; n = 3) was subtracted
from the other incubations.
Measurement of DMBA-DNA adduct formation
Confluent cultures of MCF-7 cells in 75 cm2 flasks were exposed
to 0.1 mg ml–1 [3H]DMBA in the presence of the indicated concen-
trations of galangin for 8 h. Cells were washed twice with cold
phosphate-buffered saline (PBS), trypsinized and pelleted. Nuclei
were isolated by incubating the cells for 10 min on ice in 10 mM
Tris-HCl, pH 7.5, with 320 mM sucrose, 5.0 mM magnesium chlo-
ride and 1% Triton X-100. The nuclei were pelleted by centrifuga-
tion at 800 g for 10 min at 4°C, and this digestion was repeated
once. Nuclei were then lysed with 1% sodium dodecyl sulphate
(SDS) in 0.5 M Tris, 20 mM EDTA and 10 mM NaCl, pH 9.0,
followed by treatment with 20 mg ml–1 proteinase K for 6 h at
48°C. Protein and peptides were precipitated by the addition of
NaCl to final concentration of 1 M and centrifuged at 500 g for 30
min at 4°C. Genomic DNA was then isolated from supernatant by
repeated ethanol precipitation as described in Miller et al (1988).
DNA isolated by this method exhibited a 260/280 ratio of > 1.9.
The amount of DNA was measured by spectrophotometry and the
adducts were quantified by liquid scintillation counting in Ecoscint
A (National Diagnostics, Atlanta, GA, USA).
Measurement of cell growth
MCF-7 cells were plated out in 24-well plates at 25 000 cell per
well and allowed to attach for 24 h. DMBA was added at the
indicated concentrations with either DMSO (control) or 5.0 mM
galangin in fresh media. Total cell growth was assayed after 3 days
using sulphorhodamine (Rubinstein et al, 1990).
CYP1A1 activity in intact MCF-7 cells
MCF-7 cells in 24-well plates were treated with 1 ml growth
medium containing 1 mM DMBA for 24 h in the presence of
DMSO or the indicated concentrations of galangin. At the end of
the incubation, the medium was removed and the wells were
washed two times with fresh medium. Ethoxyresorufin-O-de-
ethylase (EROD) activity, which is a specific assay of the bioacti-
vation capacity of CYP1A1, was determined in intact cells as
described in Kennedy and Jones (1994) using 5 mM ethoxyre-
sorufin (ETRF) in growth medium as a substrate in the presence of
1.5 mM salicylamide to inhibit conjugating enzymes (Lubinski et
al, 1994). The assay was carried out at 37°C. The fluorescence of
resorufin generated by the conversion of ETRF by CYP1A1 was
measured every 10 min for 60 min in a CytoFlor II multiwell
fluorescence plate reader (PerSeptive Biosystems, Framingham,
MA, USA), with an excitation of 530 nm and emission at 590 nm.
Microsomal CYP1A1 activity
MCF-7 cells were treated with 1 mM DMBA for 24 h to induce
CYP1A1 EROD activity. Microsomes were isolated as follows:
the cells were washed once with PBS, trypsinized and pelleted by
centrifugation at 800 g for 10 min at 4°C. The pellet was washed in
PBS, repelleted, then resuspended in 0.25 M sucrose, 10 mM Tris-
HCl, pH 7.5, with protease inhibitors (100 mg ml–1 phenylmethyl-
sulphonylfluoride, 300 mg ml–1 EDTA, 0.5 mg ml–1 leupeptin, 0.5
mg ml–1 aprotinin and 0.7 mg ml–1 Pepstatin A). The cells were
sonicated for 30 s on ice using a Branson Sonifier at setting 2. The
sonicate was centrifuged at 10 000 g for 10 min at 4°C and the
supernatant was centrifuged at 500 000 g for 15 min
at 4°C. The resulting microsomal pellet was resuspended in the
above buffer and the protein assayed by the Bradford method
(1976). Aliquots of microsomes were stored at – 80°C. CYP1A1
activity was determined by EROD assay in the following manner:
for Figure 5A, 10 mg of microsomes were brought up to 100 ml
with PBS, pH 7.2, 400 nM ETRF was added, along with DMSO or
the indicated concentrations of galangin. The reaction was
initiated by the addition of 250 mM NADPH. The reaction mixture
was transferred to a 96-well plate and EROD activity was deter-
mined in a Cytoflor II Fluorescence Plate Reader as described
above. For Figure 5B, 250 mM NADPH and 100–1600 nM ETRF
were added to 3 ml of PBS, pH 7.2, 410 ml aliquots were removed
to which DMSO or the indicated concentration of galangin were
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added. The reaction was initiated by the addition of 45 mg of
microsomal protein (final volume was 450 ml) and gently
vortexed. Four 100-ml aliquots (10 mg per assay) of each were
removed, placed in a 96-well plate and assayed as above. A
standard curve was constructed using resorufin.
Reverse transcription polymerase chain reaction
(RT-PCR)
Confluent MCF-7 cells were treated with a combination of
galangin and 1 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or
250 nM DMBA for 6 h, or with galangin alone for 24 h. The cells
were washed twice with PBS and total RNA was isolated using
Trizol reagent (GibcoBRL, Gaithersburg, MD, USA). Semi-quan-
titative RT-PCR for CYP1A1 and glyceraldehyde-3-phosphate
dehydrogenase (GPDH) was performed in the presence of 1.5 mCi
[32P]dATP (DuPont/NEN, Wilmington, DE, USA) using the
primer sequences and conditions of Dohr et al (1995). cDNA was
synthesized from 10 mg total RNA using a Stratagene RT-PCR kit
(LaJolla, CA, USA) as instructed. The optimum cycle number that
fell within the exponential range of response for both CYP1A1 (23
cycles) and GPDH (19 cycles) was used. Following PCR, 5 ml of
high-density sample buffer was added to the samples and they
were subjected to electrophoresis on a 10% Tris–borate–EDTA
(TBE) gel in 1 ´ TBE running buffer (all components from Novex,
San Diego, CA, USA). The gel was dried and the results were
visualized and quantified on a BioRad GS-363 Molecular Imaging
System (Hercules, CA, USA). Graphs of the resulting data were
generated by normalizing CYP1A1 to GPDH.
CAT–b-galactosidase assays
MCF-7 cells were plated at 60 000 cells per well in 24-well plates.
After 24 h the cells were transiently transfected with 12.0 mg
of a chloramphenicol acetyltransferase (CAT) reporter vector
containing the full length rat CYP1A1 promoter (pMC6.3K;
Sogawa et al, 1986) using LipofectAmine (GibcoBRL) as directed.
To control for transfection efficiency, the cells were co-transfected
with 1.0 mg of pCMZ vector containing b-galactosidase
(Clonetech Labs, Palo Alto, CA, USA). After a further 24 h, the
cells were treated with 1 nM TCDD or 250 nM DMBA in the pres-
ence of DMSO (control) or galangin for 6 h. The amount of CAT
transcription was determined using an ELISA assay (Boehringer
Mannheim, Indianapolis, IN, USA) as directed. Activity of b-
galactosidase was determined by the method of Rosenthal (1987).
The amount of CAT transcription was normalized to b-galactosi-
dase transcription.
Statistical analysis
Statistical analyses were performed using StatView Statistical
Analysis software (SAS Institute, San Francisco, CA, USA).
Differences between group mean values were determined by a
one-factor analysis of variance (ANOVA), followed by Fisher
PSLD post-hoc analysis for pair wise comparison of means.
RESULTS
Effect of galangin on the metabolism of [3H]DMBA
MCF-7 cells were incubated with [3H]DMBA in the presence or
absence of galangin for 24 h and the catabolism of DMBA was
determined by thin-layer chromatography. After 24 h, 65 ± 2.1%
(3.1  ± 0.1 nmoles of DMBA per flask per 24 h) of the parent
compound had been converted to metabolites in untreated cells.
Galangin caused a dose-dependent inhibition of [3H]DMBA
catabolism (Figure 1).
The effect of galangin on the formation of adducts between
metabolites of DMBA and DNA in MCF-7 cells was examined. In
control cultures, exposure to 0.1 mg ml–1 [3H]DMBA for 8 h
resulted in the formation of 3035 ± 168 fmoles adducts per mg
DNA. Exposure of the cells to [3H]DMBA in the presence of
galangin inhibited DMBA-DNA adduct formation in a dose-
dependent manner (Figure 2).
We measured the growth of MCF-7 cells after 3 days of incuba-
tion with increasing concentrations of DMBA in the presence or
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Figure 1 Effect of galangin on the metabolic catabolism of [3H]DMBA.
MCF-7 cells were exposed to 0.1 mg ml–1 [3H]DMBA in the presence of
DMSO (vehicle control), 1 mM, or 10 mM galangin for 24 h. [3H]DMBA and
metabolites were extracted and analysed by thin-layer chromatography. Each
bar represents the mean of 3 determinations ± standard error (s.e.). DMBA
metabolism in cultures treated with galangin was statistically different from
controls (P < 0.05)
Figure 2 Effect of galangin on [3H]DMBA-DNA adduct formation. MCF-7
cells were incubated with 0.1 mg ml–1 [3H]DMBA in the presence of DMSO, or
the indicated concentrations of galangin for 8 h. DNA was extracted and
analysed for incorporation of [3H]DMBA metabolites as described. Each bar
represents the mean of 4 determinations ± s.e. Adduct formation in all
galangin-treated samples was statistically different from controls (P < 0.05)
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absence of 5 mM galangin. Galangin completely inhibited DMBA-
induced cytotoxicity at the concentrations tested (Figure 3).
Galangin at the tested concentration had no effect on cell growth
by itself (data not shown).
Effect of galangin on CYP1A1 activity
We measured the activity of CYP1A1 using the EROD assay,
which is specific for the CYP1A1 enzyme family. There was no
EROD activity in MCF-7 cells in the absence of DMBA treatment.
Treatment of cells with DMBA caused a dose-dependent increase
in EROD activity (data not shown). We measured the EROD
activity in intact cells which had been exposed to 1 mM DMBA in
the presence of galangin. Galangin caused a dose-dependent inhi-
bition of EROD activity with an IC50 of less than 1 mM (Figure 4).
The EROD activity in microsomes isolated from cells treated with
1 mM DMBA was potently inhibited by galangin in a dose-dependent
manner, with an IC50 of approximately 30 nM (Figure 5A). Micro-
somal EROD activity with or without galangin was also measured in
the presence of different substrate concentration and the kinetics of
enzyme inhibition by galangin were analysed by double-reciprocal
(Lineweaver-Burk) analysis (Figure 5B). The Vmax of the enzyme
shifted from 5.55 pmoles per min per 10 mg microsomes in the
absence of galangin to 2.56 or 1.67 pmoles per min per 10 mg in the
presence of 25 or 50 nM galangin, while the Km remained unchanged,
indicating a non-competitive type of inhibition.
Effect of galangin on CYP1A1 expression
Treatment of MCF-7 cells with 1 nM of the known AhR ligand
TCDD for 6 h resulted in a 40-fold increase in CYP1A1 mRNA
compared to DMSO control, as determined by semi-quantitative
RT-PCR. This increase was inhibited by galangin in a dose-
dependent manner (Figure 6A). Treatment of the cells with 250 nM
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Figure 3 Effect of galangin on DMBA-induced cytotoxicity. MCF-7 cells
were plated out at 25 000 cells per well in 24-well plates. After 24 h, the
medium was changed with medium containing the indicated concentrations
of DMBA and DMSO (vehicle control) or 5 mM galangin. After 3 days cell
growth was measured with sulphorhodamine. Each point represents the
mean of 4 determinations ± s.e. Cell growth was significantly different in
galangin-treated cultures beginning at 100 nM DMBA (P < 0.05)
Figure 4 Effect of galangin on DMBA-induced CYP1A1 activity in intact
cells. MCF-7 cells were treated with 1 mM DMBA in the presence of the
indicated concentrations of galangin for 24 h. CYP1A1 activity was measured
by EROD assay in intact cells as described. EROD activity in control cultures
was 4.01 ± 0.12 pmoles per min for each well. Each point represents the
mean of 4 determinations ± s.e. EROD activity in all galangin-treated
samples was statistically different from controls (P < 0.05)
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Figure 5 Effect of galangin on microsomal CYP1A1 activity. Microsomes
were isolated from MCF-7 cells treated with 1 mM DMBA. (A) The CYP1A1
activity in 10 mg of microsomes was measured by EROD assay in the
presence of 400 nM ETRF and the indicated concentrations of galangin. Each
point represents the average of 4 determinations ± s.e. EROD activity in
controls was 2.33 ± 0.1 pmoles per min per 10 mg. EROD activity in all
galangin-treated samples was statistically different from controls (P < 0.05).
(B) EROD activity in 10 mg of microsomes was measured in the presence of
0 (n n), 25 (u u), or 50 nM (l l) galangin and 100–1600 nM ETRF and a double-
reciprocal (Lineweaver-Burk) plot was generated. Each point represents the
mean of 4 determinations1344 HP Ciolino and GC Yeh
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DMBA resulted in a tenfold increase in CYP1A1 mRNA, which
was also inhibited by galangin (Figure 6B).
The effect of galangin on the transcription of a CAT reporter
vector controlled by the CYP1A1 promoter was determined by
transient transfection studies. Treatment of transfected cells for 6 h
with 1 nM TCDD caused a sevenfold increase in CAT transcrip-
tion. This was inhibited in the presence of galangin in a dose-
dependent manner (Figure 7). DMBA at 250 nM induced a
threefold increase in transcription that was also inhibited by
galangin.
Treatment of MCF-7 cells with galangin alone for 24 h resulted
in a dose-dependent increase in CYP1A1 mRNA (Figure 8). This
increase was blocked by the RNA polymerase inhibitor actino-
mycin D, indicating that the increase in mRNA was the result of
transcriptional activation (data not shown).
DISCUSSION
Current cancer prevention strategy is based on the growing aware-
ness of the powerful anti-carcinogenic activities of plant-based
diets. The central tenet of this strategy is that minor dietary
constituents inhibit carcinogenesis through different mechanisms
of action. The steps between exposure to a procarcinogen and the
transformation of a normal cell to a cancer cell begin with the acti-
vation of the procarcinogen by cytochrome P450 enzyme(s). This
generates metabolites which may be converted to easily excreted
forms by Phase II enzymes, but also generates epoxides which are
highly electrophilic and carcinogenic, capable of reacting with
DNA and causing mutations. One mechanism of action of the
so-called ‘blocking’ type of chemopreventive agent, as classified
by Wattenburg (1985), is the inhibition of the procarcinogen acti-
vation step. In the present study we have investigated the effect of
the dietary flavonoid galangin on the carcinogen activation
pathway mediated by the AhR. Galangin is of particular interest
because its effects on other in vitro mechanisms relevant to
chemoprevention has been extensively studied (Critchfield et al,
1994; Eaton et al, 1996; Kao et al, 1998), but there is, to our
knowledge, no study which has examined its effect on the AhR
and the pathway it regulates.
We assessed the effect of galangin on the activation of DMBA.
Galangin inhibited the catabolic breakdown of DMBA (Figure 1).
Since the parent compound does not react with DNA, we hypothe-
sized that galangin would decrease DMBA-DNA adduct forma-
tion, which proved true (Figure 2). In the tissue culture setting,
DMBA inhibits cell growth because of DNA adduct formation. We
reasoned that decreased adduct formation would therefore reduce
the cytotoxicity of DMBA in vitro. In fact, at the concentration
tested, galangin completely abolished the cytotoxic effect of
DMBA (Figure 3). Galangin itself was not cytotoxic at the tested
concentration. These experiments indicate that galangin inhibits
the activation of DMBA to genotoxic metabolites. There is, to our
knowledge, no study assessing the physiologically relevant
concentrations that galangin may achieve, but other flavonoids
have been measured in the plasma and some tissues of humans in
the range of concentrations used in this study (Morton et al, 1997;
Hollman and Katan, 1998). Moreover, these concentrations corre-
spond to plasma concentrations found in rats fed with a flavonoid-
enriched diet (Manach et al, 1995).
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Figure 6 Effect of galangin on the induction of CYP1A1 mRNA by TCDD or DMBA. MCF-7 cells were treated with 10 nM TCDD or 250 nM DMBA in the
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We next examined the mechanism(s) of galangin’s action. The
activity of CYP1A1 was measured by EROD assay, a specific
indicator of the CYP1A1 bioactivation capabilities. Under condi-
tions of AhR activation, the major DMBA activating isozyme in
MCF-7 cells is CYP1A1 (Christou et al, 1994). These cells also
express CYP1B1, but it is unclear whether this isozyme can
metabolize DMBA (Shimada et al, 1997), or whether CYP1B1
possess significant EROD activity (Dohr et al, 1995; Shimada
et al, 1997). Co-treatment of the cells with DMBA and increasing
concentrations of galangin resulted in a dose-dependent inhibition
of DMBA-induced EROD activity in intact cells (Figure 4). We
could not determine, from this experiment, whether galangin’s
effect was as a result of inhibition at the enzyme level or through
a disruption of the signal transduction pathway leading to the
transcriptional activation of the CYP1A1 gene. We therefore
performed EROD assays on microsomes isolated from DMBA-
treated cells. Galangin proved to be a potent inhibitor of micro-
somal EROD activity (Figure 5A). Previous studies have shown
that the related flavonol quercetin inhibits EROD activity in rat
hepatic microsomes in a competitive fashion (Sousa and Marletta,
1985), a result we confirmed in MCF-7 microsomes (data not
shown). Analysis of the kinetics of inhibition by galangin,
however, revealed that galangin inhibits EROD activity in a non-
competitive manner (Figure 5B). Thus, the interaction of galangin
with CYP1A1 is different than the structurally similar quercetin.
DMBA causes the transcriptional activation of the CYP1A1
gene through the AhR. Although the results of the microsomal
EROD assays indicate that direct enzyme inhibition by galangin
can account for the decrease in DMBA-induced EROD activity in
intact cells, we also tested the hypothesis that galangin may disrupt
the transciptional activation of CYP1A1. When MCF-7 cells were
treated with 250 nM DMBA for 6 h, there was an approximately
tenfold increase in CYP1A1 mRNA compared to DMSO control.
Co-treatment with galangin caused a dose-dependent inhibition of
the DMBA-induced increase in CYP1A1 mRNA (Figure 6B).
Galangin also inhibited the increase in CYP1A1 mRNA by the
prototypical AhR ligand TCDD (Figure 6A). Galangin also inhib-
ited the DMBA- or TCDD-induced transcription of CAT in a
reporter vector controlled by the CYP1A1 promoter (Figure 7). We
also observed that treatment of the cells with galangin alone for a
longer period of time (24 h) could induce a mild increase
(compared to DMBA or TCDD) in CYP1A1 mRNA (Figure 8).
This increase was blocked by the RNA polymerase inhibitor
actinomycin D, which prevents de novo RNA synthesis resulting
from transcriptional activation (data not shown). These results are
consistent with the hypothesis that galangin is a weak ligand of the
AhR and is able to compete for the AhR with traditional activators
of the receptor, resulting overall in a decrease in CYP1A1 mRNA
caused by other, more potent AhR ligands. The induction of
CYP1A1 mRNA and the inhibition of CYP1A1 EROD activity by
galangin may indicate that it is a natural substrate of this metabolic
pathway in MCF-7 cells, but this was not examined in the present
study.
Known ligands of the AhR are, for the most part, man-made
chemicals; natural ligands have been postulated but, with the
exception of indolo[2,3]-carbazole (Jellinck et al, 1993), remain
unidentified. We have hypothesized elsewhere (Ciolino et al,
1998) that dietary polyphenolic compounds are natural ligands of
the AhR and galangin appears to be such a compound. These
experiments demonstrate that galangin inhibits carcinogen activa-
tion in MCF-7 cells at two levels: through direct inhibition of
CYP1A1 enzyme activity and by inhibiting the increase in
CYP1A1 transcription caused by AhR ligands. There is no study,
to our knowledge, on the chemopreventive effect of galangin in
animal models of carcinogenesis. Based on our data, galangin may
be a promising candidate for in vivo chemoprevention studies.
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Figure 7 Effect of galangin on TCDD- or DMBA-induced CAT transcription.
MCF-7 cells were transfected with an aryl hydrocarbon-responsive CAT
reporter vector containing the full length CYP1A1 promoter and a b-
galactosidase vector as described in Materials and Methods. Cells were
treated with 1 nM TCDD or 250 nM DMBA for 6 h in the presence of DMSO
(control) or the indicated concentrations of galangin. The amount of CAT
transcription was normalized to the amount of b-galactosidase transcription.
n = 4 ± s.e. The amount of CAT transcription in galangin-treated cultures was
statistically different from TCDD- or DMBA-treated cultures (P < 0.05)
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Figure 8 Effect of galangin on CYP1A1 mRNA. MCF-7 cells were treated
with the indicated concentrations of galangin for 24 h. For graph, CYP1A1
mRNA was normalized to GPDH mRNA ± s.e. The amount of CYP1A1
mRNA was statistically significant from controls in cultures treated with 5 mM,
but not 1 mM, galangin
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